Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis.
Hiroaki KanzakiSadahisa OgasawaraTomomi OkuboNorio ItokawaRyohei YoshinoKentaro FujimotoTadayoshi KogureSae YumitaTakamasa IshinoKeita OgawaTerunao IwanagaMiyuki NakagawaKisako FujiwaraRyuta KojimaKeisuke KorokiMasanori InoueKazufumi KobayashiNaoya KanogawaSoichiro KiyonoMasato NakamuraTakayuki KondoRyo NakagawaShingo NakamotoRyosuke MuroyamaEi ItobayashiMasanori AtsukawaJun KatoNaoya KatoPublished in: Drugs - real world outcomes (2023)
Cabozantinib has recently been administered to a diverse range of patients, including those who were not enrolled in the CELESTIAL trial. Deliberate dose reduction could potentially offer clinical benefits to patients with impaired liver function. Furthermore, managing adverse events by reducing the dose could play a crucial role in extending the duration of treatment with cabozantinib. The preprint version of this work is available on https://www.researchsquare.com/article/rs-2655181/v1 .